Absorbable bone wax and preparation method thereof

Through the combination of multi-arm polyethylene glycol derivatives, poloxamer and hydroxyapatite, combined with calcium phosphate substances, the problems of poor absorption and harsh storage conditions of traditional bone wax materials are solved, and high adhesion and Biocompatible bone wax material promotes bone tissue repair and reduces operational difficulty and toxicity.

CN119015475APending Publication Date: 2024-11-26SHANGHAI RUINING BIOTECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411279559.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-12
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Traditional bone wax materials are difficult to absorb in the body, which may cause infection, and the gap is too small, hindering the recovery of bone tissue and increasing the patient's pain. At the same time, the existing storage conditions for resorbable bone wax are harsh and costly.

Method used

Using a combination of multi-arm polyethylene glycol derivatives, poloxamer and hydroxyapatite, the combined effect of the multi-arm polyethylene glycol derivatives with poloxamer and increase the hydroxyapatite. Adhesion effect forms bone wax materials with high adhesion and plasticity, and promotes bone tissue repair and binding through calcium phosphate substances.

Benefits of technology

Improve the adhesion and biocompatibility of bone wax materials, shorten the collapse time, enhance adhesion and biocompatibility, promote the repair of bone tissue, reduce the toxicity and operation difficulty of the material, and achieve good results. sealing effect and operability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005041204280000051
    Figure BDA0005041204280000051
  • Figure BDA0005041204280000061
    Figure BDA0005041204280000061
  • Figure BDA0005041204280000071
    Figure BDA0005041204280000071
Patent Text Reader

Abstract

The invention discloses absorbable bone wax, which is prepared from the following raw materials: a multi-arm polyethylene glycol derivative, a medicine auxiliary material, a calcium phosphate substance and a liquid material. Under the combined action of the multi-arm polyethylene glycol derivative, the medicine auxiliary material and the calcium phosphate substance, the overall adhesion and biocompatibility of the absorbable bone wax material can be improved, and the stability of the bone wax material is improved. The absorbable bone wax disclosed by the invention is soft in texture, good in ductility, short in collapsing time, short in degradation time, good in healing promotion performance, non-toxic, excellent in operability and simple in preparation process, and the prepared absorbable bone wax has a good plugging effect and can be widely applied to the field of orthopedic hemostasis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to absorbable bone wax and a preparation method thereof, and relates to A61L, in particular to the field of surgical adhesives or bonding agents. Background Art

[0002] Bone wax is a material that blocks capillary bleeding in the bone marrow by physical means. Bone wax absorbs water in the blood to promote the concentration of platelets, thereby enhancing the aggregation speed and ability of platelets and achieving the coagulation effect. After absorbing water, bone wax forms a gel, which seals the wound and increases the hemostatic effect. After absorbing water, bone wax also has a certain compression effect on blood vessels, further promoting hemostasis. The bone wax used in traditional methods is mostly a combination of beeswax and vaseline, which has a certain plasticity, but cannot be absorbed by the human body. It is easy to cause infection if left in the body. In addition, the gaps in traditional bone wax are too small, and bone tissue cannot grow and recover through the bone wax. Postoperative debridement is often required, which increases the pain of patients.

[0003] Chinese invention patent CN201910154768.7 discloses an absorbable bone wax and its preparation method and application. A polymer interlocking network structure is constructed by α-tocopheryl succinate polyethylene glycol ester and polycarboxyl-substituted chitosan, and the strontium ions are effectively stabilized by the chelation of polycarboxyl-substituted chitosan on strontium ions, giving the absorbable bone wax the characteristics of controllable degradation and excellent viscosity. However, it needs to be soaked in PBS solution before use, which is inconvenient to use. Chinese invention patent CN201910154768.7 discloses an absorbable hemostatic bone wax and its preparation method. The bone wax product prepared by utilizing the degradability of polycaprolactone and polyethylene glycol, the biological activity of hydroxyapatite, and the rapid hemostasis of thrombin not only has excellent physical blocking, packing performance and hemostatic effect, but also can be completely biodegraded and absorbed. However, the thrombin used has strict requirements on the storage environment and the storage cost is high. Summary of the invention

[0004] In order to develop a bone wax material with good biocompatibility, high adhesion and good plasticity, the first aspect of the present invention provides an absorbable bone wax, and the preparation raw materials include multi-arm polyethylene glycol derivatives, pharmaceutical excipients, calcium phosphate substances, and liquid materials.

[0005] As a preferred embodiment, the multi-arm polyethylene glycol derivative is an aldehyde-terminated multi-arm polyethylene glycol derivative, the number of arms of the multi-arm polyethylene glycol derivative is 2-8, and the molecular weight of the multi-arm polyethylene glycol derivative is 5000-400000 Da.

[0006] As a preferred embodiment, the pharmaceutical excipient is selected from one or a combination of gelatin, carboxymethyl cellulose (CMC), coconut oil ester, poloxamer, polyethylene glycol (PEG).

[0007] As a preferred embodiment, the pharmaceutical excipient is poloxamer.

[0008] As a preferred embodiment, the poloxamer type includes at least one of F127, F68, L64, L61, and P123.

[0009] As a preferred embodiment, the poloxamer type is F127.

[0010] As a preferred embodiment, the particle size of the calcium phosphate material is 5-20 μm.

[0011] As a preferred embodiment, the calcium phosphate material includes at least one of hydroxyapatite, tricalcium phosphate, tetracalcium phosphate, calcium pyrophosphate, calcium hydrogen phosphate, and calcium dihydrogen phosphate.

[0012] As a preferred embodiment, the calcium phosphate substance is hydroxyapatite.

[0013] As a preferred embodiment, the liquid material includes at least one of ultrapure water, PBS solution, and physiological saline.

[0014] As a preferred embodiment, the liquid material is ultrapure water.

[0015] The applicant found in the experiment that the bone wax prepared by mixing a combination of multi-arm polyethylene glycol derivatives, poloxamer and hydroxyapatite can improve the adhesion and biocompatibility of the overall material, and the stability of the bone wax is relatively high. It is speculated that the possible reasons are: the combination of multi-arm polyethylene glycol derivatives, poloxamer and hydroxyapatite, the aldehyde group of the multi-arm polyethylene glycol derivative can work together with poloxamer to increase the adhesion effect with hydroxyapatite, the multi-arm polyethylene glycol derivative increases the contact area with hydroxyapatite, and the presence of poloxamer improves the binding of hydroxyapatite with the multi-arm polyethylene glycol derivative, shortening the disintegration time of the bone wax material. And the joint action of the multi-arm polyethylene glycol derivative and poloxamer can make the bone wax material have a certain ductility, high consistency, strong adhesion, and not easy to fall off.

[0016] A second aspect of the present invention provides a method for preparing absorbable bone wax, comprising the following steps:

[0017] S1: Mix the multi-arm polyethylene glycol derivative and the drug excipient with the liquid material respectively, and after they are completely dissolved, obtain a multi-arm polyethylene glycol derivative solution and a drug excipient solution for standby use;

[0018] S2: Mix the multi-arm polyethylene glycol derivative solution, the drug excipient solution, and the calcium phosphate substance according to a weight ratio to obtain bone wax.

[0019] As a preferred embodiment, the mass concentration of the multi-arm polyethylene glycol derivative solution is 10%-30%, and the mass concentration of the pharmaceutical excipient solution is 2%-15%.

[0020] As a preferred embodiment, the mass concentration of the multi-arm polyethylene glycol derivative solution is 20%-30%, and the mass concentration of the pharmaceutical excipient solution is 5%-10%.

[0021] As a preferred embodiment, the mass concentration of the multi-arm polyethylene glycol derivative solution is 25%, and the mass concentration of the pharmaceutical excipient solution is 5%.

[0022] As a preferred embodiment, the mass volume ratio of the calcium phosphate substance, the multi-arm polyethylene glycol derivative solution, and the drug excipient solution is (1-4) g: (1-10) mL: 1 mL.

[0023] As a preferred embodiment, the mass volume ratio of the calcium phosphate substance, the multi-arm polyethylene glycol derivative solution, and the drug excipient solution is (2-3) g: (1-5) mL: 1 mL.

[0024] As a preferred embodiment, the mass volume ratio of the calcium phosphate substance, the multi-arm polyethylene glycol derivative solution, and the drug excipient solution is 2g:1mL:1mL.

[0025] The calcium phosphate material, the multi-arm polyethylene glycol derivative solution and the drug excipient solution of the present invention adopt an optimal mass-to-volume ratio. The multi-arm polyethylene glycol derivative solution can undergo a chemical cross-linking reaction with bone tissue and work together with poloxamer to further improve the strength and adhesion of the bone wax material. The calcium phosphate material can promote the growth and repair of new bone tissue. After being mixed with other components, it can promote the combination and regeneration of the material with surrounding bone tissue through surface adsorption and release of calcium ions, and has good biocompatibility and bone repair guidance.

[0026] Compared with the prior art, the present invention has the following beneficial effects:

[0027] (1) The absorbable bone wax of the present invention uses a multi-arm polyethylene glycol derivative, a pharmaceutical excipient, and a calcium phosphate substance to work together to improve the overall adhesion and biocompatibility of the absorbable bone wax material and enhance the stability of the bone wax material.

[0028] (2) The absorbable bone wax and multi-arm polyethylene glycol derivative solution of the present invention adopts a mass concentration of 25%, which can achieve uniform dissolution and dispersion of the solution, obtain a material with good plasticity and a bone wax form, and has excellent adhesion to bones.

[0029] (3) The absorbable bone wax of the present invention adopts a drug excipient solution with a mass concentration of 5%, which can obtain a bone wax material in the form of plasticine, has excellent plasticity and is easy to use.

[0030] (4) The absorbable bone wax, calcium phosphate substance, multi-arm polyethylene glycol derivative solution, and drug excipient solution of the present invention adopt a mass volume ratio of (1-4) g: (1-10) mL: 1 mL, which can obtain a plastic bone wax material with high adhesion and good biocompatibility.

[0031] (5) The absorbable bone wax of the present invention has a soft texture, good ductility, short disintegration time, short degradation time, good healing performance, non-toxicity, excellent operability, and a simple preparation process. The prepared absorbable bone wax has a good blocking effect and can be widely used in the field of orthopedic hemostasis. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 This is a test diagram of the adhesion performance of the bone wax material prepared in Example 5-9 to the bone, from right to left are Example 5-9;

[0033] Figure 2 This is a test diagram of the anti-collapse performance of the bone wax material prepared in Example 14;

[0034] Figure 3 This is a degradation performance test diagram of the bone wax material prepared in Example 14, from left to right: before degradation, during degradation, and after degradation. DETAILED DESCRIPTION

[0035] Experiment 1

[0036] The invention discloses an absorbable bone wax, wherein the raw materials for preparing the wax include multi-arm polyethylene glycol derivatives, pharmaceutical excipients, calcium phosphate substances and liquid materials.

[0037] The number of arms of the multi-arm polyethylene glycol derivative is 4, and the molecular weight of the multi-arm polyethylene glycol derivative is 10000Da; 4arm-PEG-CHO-10kDa, the mass fraction is 25wt%

[0038] The multi-arm polyethylene glycol derivative: model: 4arm-PEG-CHO-10kDa, manufacturer: Xiamen Sinobond.

[0039] A method for preparing absorbable bone wax comprises the following steps:

[0040] S1: Mix the multi-arm polyethylene glycol derivative and the drug excipient with the liquid material respectively, and after they are completely dissolved, obtain a multi-arm polyethylene glycol derivative solution and a drug excipient solution for standby use;

[0041] S2: Mix the multi-arm polyethylene glycol derivative solution, the drug excipient solution, and the calcium phosphate substance according to a weight ratio to obtain bone wax.

[0042] The liquid material is ultrapure water.

[0043] Among them: Gelatin: CAS: 9000-70-8, Manufacturer: Sigma Aldrich

[0044] CMC:CAS:9004-32-4,Manufacturer:adamas-beta

[0045] F127 (Poloxamer 407): Batch number: GNG06521B, Manufacturer: BASF (China) Co., Ltd.

[0046] PEG: CAS: 25322-68-3, MN8000, manufacturer: Shanghai MacLean Biochemical Technology Co., Ltd.

[0047] The specific parameters of Experiment 1 are shown in Table 1 below.

[0048] Table 1

[0049]

[0050] It can be seen from Table 1 that in the absence of hydroxyapatite, the other two groups are mixed into a transparent liquid without gelation and without bone wax.

[0051] When one component is gelatin, it does not gel or forms non-adhesive bone wax.

[0052] When a component is hydroxyapatite, it can form a bone wax morphology.

[0053] Figure 1 The adhesion test results of Example 5 to Example 9 (from right to left) are shown in the figure. It can be seen from the figure that when gelatin is used as one of the components, the overall mixture cannot adhere to the surface of pig bones; when other components are used, the whole is in the form of bone wax, and the overall mixture has adhesion.

[0054] Experiment 2

[0055] The invention discloses an absorbable bone wax, wherein the raw materials for preparing the wax include multi-arm polyethylene glycol derivatives, pharmaceutical excipients, calcium phosphate substances and liquid materials.

[0056] The number of arms of the multi-arm polyethylene glycol derivative is 4, and the molecular weight of the multi-arm polyethylene glycol derivative is 10000 Da; it is 4arm-PEG-CHO-10 kDa, and the mass fraction is 25 wt%.

[0057] The multi-arm polyethylene glycol derivative: model: 4arm-PEG-CHO-10kDa, manufacturer: Xiamen Sinobond.

[0058] A method for preparing absorbable bone wax comprises the following steps:

[0059] S1: Mix the multi-arm polyethylene glycol derivative and the drug excipient with the liquid material respectively, and after they are completely dissolved, obtain a multi-arm polyethylene glycol derivative solution and a drug excipient solution for standby use;

[0060] S2: Mix the multi-arm polyethylene glycol derivative solution, the drug excipient solution, and the calcium phosphate substance according to a weight ratio to obtain bone wax.

[0061] The liquid material is ultrapure water.

[0062] Among them: CMC: CAS: 9004-32-4, manufacturer: adamas-beta

[0063] F127 (Poloxamer 407): Batch number: GNG06521B, Manufacturer: BASF (China) Co., Ltd.

[0064] PEG: CAS: 25322-68-3, MN8000, manufacturer: Shanghai MacLean Biochemical Technology Co., Ltd.

[0065] The specific parameters of Experiment 2 are shown in Table 2. The performance test results are shown in Table 3.

[0066] Table 2

[0067]

[0068]

[0069] Table 3

[0070] Gel formation Adhesion Average consistency Start of collapse time Example 10 Unable to shape No adhesion 13mm 1min Embodiment 11 Bone wax morphology No shedding after 1 hour 20mm 3min Example 12 Bone wax morphology No shedding after 1 hour 20mm 2min Embodiment 13 Bone wax morphology No shedding after 1 hour 30mm 2.5min Embodiment 14 Bone wax morphology No shedding after 1 hour 30mm 5min Embodiment 15 Bone wax morphology No shedding after 1 hour 20mm 4min Example 16 Bone wax morphology No shedding after 1 hour 20mm 4min

[0071] It can be seen from Table 3 that when hydroxyapatite, PEG and CMC are mixed, the overall mixture has no plasticity, no adhesion and low consistency; when hydroxyapatite, PEG and F127 are mixed, the mixture has good plasticity, good adhesion and is not easy to fall off, but it collapses quickly; when hydroxyapatite, multi-arm polyethylene glycol derivatives and F127 are mixed, the mixture has good plasticity, good adhesion and is not easy to fall off, the consistency value is the largest, the collapse is slow, and it takes 5 minutes to start collapsing.

[0072] Experiment 3

[0073] The invention discloses an absorbable bone wax, wherein the raw materials for preparing the wax include multi-arm polyethylene glycol derivatives, pharmaceutical excipients, calcium phosphate substances and liquid materials.

[0074] The number of arms of the multi-arm polyethylene glycol derivative is 4, and the molecular weight of the multi-arm polyethylene glycol derivative is 10000Da; it is 4arm-PEG-CHO-10kDa.

[0075] The multi-arm polyethylene glycol derivative: model: 4arm-PEG-CHO-10kDa, manufacturer: Xiamen Sinobond.

[0076] A method for preparing absorbable bone wax comprises the following steps:

[0077] S1: Mix the multi-arm polyethylene glycol derivative and the drug excipient with the liquid material respectively, and after they are completely dissolved, obtain a multi-arm polyethylene glycol derivative solution and a drug excipient solution for standby use;

[0078] S2: Mix the multi-arm polyethylene glycol derivative solution, the drug excipient solution, and the calcium phosphate substance according to a weight ratio to obtain bone wax.

[0079] The volume-to-mass ratio of the multi-arm polyethylene glycol derivative solution, the drug excipient solution, and the calcium phosphate substance is 1 mL: 1 mL: 2 g.

[0080] The liquid material is ultrapure water.

[0081] F127 (Poloxamer 407): Batch number: GNG06521B, Manufacturer: BASF (China) Co., Ltd.

[0082] The specific parameters of Experiment 3 are shown in Table 4 below.

[0083] Table 4

[0084]

[0085] It can be seen from Table 4 that: when different concentrations of multi-arm polyethylene glycol derivatives are mixed with hydroxyapatite and F127, the overall mixture can be molded into a bone wax form; but as the concentration of the multi-arm polyethylene glycol derivative changes, the adhesion of the formed bone wax varies greatly. When the concentration of the multi-arm polyethylene glycol derivative is higher than 30%, the multi-arm polyethylene glycol derivative is difficult to dissolve in aqueous solution. When the concentration of the multi-arm polyethylene glycol derivative is lower than 20%, the adhesion is poor. When the concentration of the multi-arm polyethylene glycol derivative is 25%, the adhesion is good, and the bone did not fall off for 1 hour.

[0086] Experiment 4

[0087] The invention discloses an absorbable bone wax, wherein the raw materials for preparing the wax include multi-arm polyethylene glycol derivatives, pharmaceutical excipients, calcium phosphate substances and liquid materials.

[0088] The number of arms of the multi-arm polyethylene glycol derivative is 4, and the molecular weight of the multi-arm polyethylene glycol derivative is 10000Da; it is 4arm-PEG-CHO-10kDa.

[0089] The multi-arm polyethylene glycol derivative: model: 4arm-PEG-CHO-10kDa, manufacturer: Xiamen Sinobond.

[0090] A method for preparing absorbable bone wax comprises the following steps:

[0091] S1: Mix the multi-arm polyethylene glycol derivative and the drug excipient with the liquid material respectively, and after they are completely dissolved, obtain a multi-arm polyethylene glycol derivative solution and a drug excipient solution for standby use;

[0092] S2: Mix the multi-arm polyethylene glycol derivative solution, the drug excipient solution, and the calcium phosphate substance according to a weight ratio to obtain bone wax.

[0093] The volume-to-mass ratio of the multi-arm polyethylene glycol derivative solution, the drug excipient solution, and the calcium phosphate substance is 1 mL: 1 mL: 2 g.

[0094] The liquid material is ultrapure water.

[0095] F127 (Poloxamer 407): Batch number: GNG06521B, Manufacturer: BASF (China) Co., Ltd.

[0096] The specific parameters of Experiment 4 are shown in Table 5 below.

[0097] Table 5

[0098]

[0099] It can be seen from Table 5 that when the concentration of F127 is higher than 10%, F127 is insoluble in aqueous solution; when the concentration of F127 is 2%, the whole is a flowing liquid and has not become bone wax; when the concentration of F127 is 5%, the whole is a plasticine-like bone wax.

[0100] Experiment 5

[0101] The invention discloses an absorbable bone wax, wherein the raw materials for preparing the wax include multi-arm polyethylene glycol derivatives, pharmaceutical excipients, calcium phosphate substances and liquid materials.

[0102] The number of arms of the multi-arm polyethylene glycol derivative is 4, and the molecular weight of the multi-arm polyethylene glycol derivative is 10000Da; it is 4arm-PEG-CHO-10kDa.

[0103] The multi-arm polyethylene glycol derivative: model: 4arm-PEG-CHO-10kDa, manufacturer: Xiamen Sinobond.

[0104] A method for preparing absorbable bone wax comprises the following steps:

[0105] S1: Mix the multi-arm polyethylene glycol derivative and the drug excipient with the liquid material respectively, and after they are completely dissolved, obtain a multi-arm polyethylene glycol derivative solution and a drug excipient solution for standby use;

[0106] S2: Mix the multi-arm polyethylene glycol derivative solution, the drug excipient solution, and the calcium phosphate substance according to a weight ratio to obtain bone wax.

[0107] The volume ratio of the multi-arm polyethylene glycol derivative solution to the drug excipient solution is 1 mL:1 mL.

[0108] The liquid material is ultrapure water.

[0109] F127 (Poloxamer 407): Batch number: GNG06521B, Manufacturer: BASF (China) Co., Ltd.

[0110] The specific parameters of Experiment 5 are shown in Table 6 below.

[0111] Table 6

[0112]

[0113] It can be seen from Table 6 that the amount of hydroxyapatite added affects the morphology of bone wax. As the amount of hydroxyapatite added increases, the overall mixture becomes a bone wax morphology. When the amount of hydroxyapatite continues to increase, the overall mixture gradually becomes a non-adhesive bone wax morphology.

[0114] Comparative Example 1

[0115] A bone wax material is prepared by preparing raw materials including 75wt% of beeswax, 15wt% of paraffin and 10wt% of palm isopropyl ester.

[0116] A method for preparing bone wax material comprises the following steps: beeswax, paraffin and palm isopropyl ester are uniformly mixed to obtain bone wax material.

[0117] The consistency of bone wax is 18.0mm. The texture of bone wax is hard and its ductility is poor. It also takes a long time to disintegrate, usually taking more than 10 minutes.

[0118] Performance Testing

[0119] 1. Consistency: Refer to the determination method of dental zinc phosphate cement in ISO1566 "Dental zinc phosphate cement" to test the consistency of absorbable bone wax: Take 1.25g of the samples of Examples 10-16 and Comparative Example 1, roll them into a ball, and use a 500g weight to press it through a plastic plate to obtain the diameter of the circle.

[0120] The diameter of the circle is used to indicate the consistency of the sample. The larger the diameter of the circle, the smaller the consistency of the sample. Three samples of the same sample are measured, and two diameters of each circle, vertical and horizontal, are measured, and the average value is taken.

[0121] 2. Adhesion performance: Take 1.25g of the test sample and apply it on the surface of the pig bone. Observe whether there is any slag falling off within 3 minutes at room temperature and whether the density is good.

[0122] Figure 1 The results showed that the bone wax of Examples 6-9 could adhere well to the surface of pig bones (size: 10mm*20mm*50mm) and was not easy to fall off.

[0123] The bone wax of Comparative Example 1 is relatively hard in texture and needs to be heated to soften the traditional bone wax before it can be attached to the surface of the pig bone.

[0124] 3. Anti-collapse performance: Take 1.25g of the bone wax of Example 14, roll it into a ball, place it in a sample bottle, add 15mL of water, turn on the shaker, and observe the anti-collapse performance of the sample at a speed of 120r / min and a water temperature of 37°C. The results are as follows: Figure 2 shown.

[0125] 4. Degradation performance: 0.2 g of the bone wax of Example 14 and Comparative Example 1 was taken, rolled into a ball, and placed in a sample bottle filled with a 6 mol / L sodium hydroxide solution. After sealing, the bottle was placed in a constant temperature water bath oscillator and degraded at a speed of 120 r / min and a water temperature of 37° C. The time for the sample to be completely degraded was observed.

[0126] Taking the sample of Example 14 as an example, after the test sample is completely degraded, the solution is turbid ( Figure 3 Right), when hydroxyapatite, multi-arm polyethylene glycol derivatives and F127 are combined, the multi-arm polyethylene glycol derivatives and F127 undergo a chemical reaction, which can stick the samples into a ball, and the sodium hydroxide solution is not easy to penetrate into the interior of the sample, resulting in a longer degradation time of the test sample; in addition, hydroxyapatite is a bioactive material with good biocompatibility that can stimulate bone formation and bone binding, and also has good thermal stability.

[0127] The degradation time of Example 14 is greater than 4 hours, and the degradation time of Comparative Example 1 is greater than 12 hours.

[0128] When 2 g of hydroxyapatite, 1 mL of F127 (mass percentage: 5%) and 1 mL of a multi-arm polyethylene glycol derivative (mass percentage: 25%) are combined, the overall mixture is in the form of bone wax, which is adhesive and does not fall off for 1 hour, and the sample has good anti-collapse performance.

Claims

1. An absorbable bone wax, characterized in that: The preparation raw materials include multi-arm polyethylene glycol derivatives, pharmaceutical excipients, calcium phosphate substances and liquid materials.

2. The absorbable bone wax according to claim 1, characterized in that: The multi-arm polyethylene glycol derivative is an aldehyde-terminated multi-arm polyethylene glycol derivative, the number of arms of the multi-arm polyethylene glycol derivative is 2-8, and the molecular weight of the multi-arm polyethylene glycol derivative is 5000-400000 Da.

3. The absorbable bone wax according to claim 1, characterized in that: The pharmaceutical excipient is selected from one or a combination of gelatin, carboxymethyl cellulose, coconut oil ester, poloxamer and polyethylene glycol.

4. The absorbable bone wax according to claim 3, characterized in that: The poloxamer type includes at least one of F127, F68, L64, L61, and P123.

5. The absorbable bone wax according to claim 1, characterized in that: The particle size of the calcium phosphate material is 5-20 μm.

6. The absorbable bone wax according to claim 5, characterized in that: The calcium phosphate material includes at least one of hydroxyapatite, tricalcium phosphate, tetracalcium phosphate, calcium pyrophosphate, calcium hydrogen phosphate, and calcium dihydrogen phosphate.

7. The absorbable bone wax according to claim 1, characterized in that: The liquid material includes at least one of ultrapure water, PBS solution, and physiological saline.

8. A method for preparing absorbable bone wax according to claim 1, characterized in that: The following steps are involved: S1: Mix the multi-arm polyethylene glycol derivative and the drug excipient with the liquid material respectively, and after they are completely dissolved, obtain a multi-arm polyethylene glycol derivative solution and a drug excipient solution for standby use; S2: Mix the multi-arm polyethylene glycol derivative solution, the drug excipient solution, and the calcium phosphate substance according to a weight ratio to obtain bone wax.

9. The method for preparing absorbable bone wax according to claim 8, characterized in that: The mass concentration of the multi-arm polyethylene glycol derivative solution is 10%-30%, and the mass concentration of the drug excipient solution is 2%-15%.

10. The method for preparing absorbable bone wax according to claim 8, characterized in that: The mass volume ratio of the calcium phosphate substance, the multi-arm polyethylene glycol derivative solution, and the drug excipient solution is (1-4) g: (1-10) mL: 1 mL.